Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects with Metastatic Solid Tumors Ended

2023-508529-29-00 Metastatic Solid Malignant tumors 9 2023-03-08
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Non-resectable locally advanced or metastatic HER2-posi 9 2023-03-08
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended

2024-510590-14-00 multiple myeloma 5 2023-03-03
Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line o… Ended

2023-508860-31-00 Stage IV colon or rectal adenocarcinoma (mCRC). 5 2023-02-28
First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended

2022-501183-17-00 Non-Small Cell Lung Cancer 7 2023-02-23
A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended

2024-515744-23-00 Relapsed or refractory (R/R) Acute lymphoblastic leukem 1 2023-02-15
A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended

2023-504111-33-00 Platinum-resistant High-grade Serous Ovarian, Primary P 4 2023-02-14
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma Ended

2023-505672-30-00 Unresectable or Metastatic Melanoma 4 2023-02-10
Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizu… Ended

2024-511538-11-00 Non resectable Hepatocellular carcinoma (HCC) 4 2023-02-07
The effect of oral folinic acid to prevent pemetrexed induced adverse events. Ended

2022-502345-10-00 Non small cell lung cancer (NSCLC), Mesothelioma, Thymo 6 2023-02-05
Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization i… Ended

2023-504342-55-00 Cohort A: • Metastatic non-small cell lung carcinoma ( 10 2023-02-02
Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-N… Ended

2024-514060-10-00 Advanced triple-negative breast cancer (TNBC), Advanced 4 2023-02-02
Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational… Ended

2024-517646-34-00 Prostate cancer 6 2023-02-01
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer Ended

2022-500808-21-00 Metastatic triple negative breast cancer 4 2023-02-01
Calcium electroporation in combination with irreversible electroporation and immunotherapy in patients with pMMR metastatic colorectal cance… Ended

2022-500045-25-00 Colorectal cancer 4 2023-01-26
A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphoma Ended

2022-501431-16-00 Relapsed or Refractory Peripheral T/NK Cell or Cutaneou 4 2023-01-17
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activ… Ended

2022-500116-18-00 Advanced Solid Tumors 3 2023-01-09
Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC Ended

2023-504112-15-00 Metastatic Non-Small Cell Lung Cancer 4 2023-01-04
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended

2023-503715-14-00 Recurrent or Refractory Classical Hodgkin Lymphoma and 9 2022-12-29
An Open-label, Randomized, Three-period, Crossover Study to compare the Pharmacokinetics of GB1211 upon dosing a capsule under fasting condi… Ended

2022-502200-67-00 Non-small Cell Lung Cancer 3 2022-12-27
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year… Ended

2024-512095-35-00 Relapsed or refractory neuroblastoma and other solid tu 9 2022-12-27
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activi… Ended

2022-500115-39-00 Advanced Solid Tumors 1 2022-12-23
A first-in-human clinical trial in adult patients with metastatic or recurrent melanoma of a personalised therapy targeting specific mutatio… Ended

2024-513062-19-00 Metastatic or recurrent melanoma 7 2022-12-22